Nifty
Sensex
:
:
22331.40
71947.55
-488.20 (-2.14%)
-1635.67 (-2.22%)

Pharmaceuticals & Drugs - Domestic

Rating :
74/99

BSE: 506820 | NSE: ASTRAZEN

7765.50
30-Mar-2026
  • Open
  • High
  • Low
  • Previous Close
  •  7811
  •  7901.5
  •  7677
  •  7931.00
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  13887
  •  107644878.5
  •  10691
  •  7201.15

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 19,398.63
  • 98.89
  • 2
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 18,998.69
  • 0.41%
  • 23.89

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 75.00%
  • 1.15%
  • 14.14%
  • FII
  • DII
  • Others
  • 2.71%
  • 5.48%
  • 1.52%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.78
  • 16.10
  • 19.61

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 31.50
  • 13.39
  • 8.99

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 36.22
  • 4.40
  • 5.24

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 108.86
  • 107.20
  • 109.49

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 21.02
  • 20.50
  • 23.46

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 63.38
  • 63.79
  • 65.69

Earnings Forecasts:

(Updated: 28-03-2026)
Description
2024
2025
2026
2027
Adj EPS
46.3
P/E Ratio
167.72
Revenue
1716.29
EBITDA
253.97
Net Income
115.74
ROA
8.92
P/B Ratio
25.20
ROE
15.62
FCFF
94.05
FCFF Yield
0.46
Net Debt
-500.97
BVPS
308.14

Quarterly Results

Standalone Figures in Rs. Crores /

Consolidated
Description
Sep 25
Sep 24
Var%
Jun 25
Jun 24
Var%
Mar 25
Mar 24
Var%
Dec 24
Dec 23
Var%
Net Sales
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Expenses
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBITDA
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
EBIDTM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
Other Income
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Interest
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Depreciation
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PBT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
Tax
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PAT
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
PATM
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
0.00%
EPS
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0
0.00
0.00
0

Annual Results

Standalone Figures in Rs. Crores

Results Balance Sheet

Standalone Figures in Rs. Crores

Cash Flow

Standalone Figures in Rs. Crores

Financial Ratios

Standalone

News Update:


  • AstraZeneca Pharma gets nod to import, market Durvalumab Solution
    17th Mar 2026, 18:20 PM

    Through this approval, Durvalumab is indicated for the treatment of patients with unresectable hepatocellular carcinoma who have not received prior systemic therapy

    Read More
  • AstraZeneca Pharma gets CDSCO nod to import Durvalumab Solution
    10th Feb 2026, 12:23 PM

    The receipt of this permission paves way for the marketing of Durvalumab Solution for Infusion 120 mg/2.4 mL and 500 mg/10 mL (Imfinzi) in India for the specified additional indication

    Read More
  • AstraZeneca Pharma gets nod to import for sale, distribution of Durvalumab Solution
    31st Jan 2026, 16:32 PM

    The company has received permission from the Central Drugs Standard Control Organisation

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.